The effects of hepatic impairment on the pharmacokinetics of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole

British Journal of Clinical Pharmacology

Volumn 59, Issue 2, 2005, Pages 160-166

  Sobue, Satoshi ^a   Tan, Keith ^b   Haug Pihale, Gertraud ^c  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c APEX GmbH   (Germany)

Author keywords

Fosfluconazole; Hepatic impairment; Pharmacokinetics

Indexed keywords

FLUCONAZOLE; FOSFLUCONAZOLE;

ABDOMINAL PAIN; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG URINE LEVEL; FEMALE; HUMAN; LABORATORY TEST; LIVER DISEASE; LIVER FUNCTION; MALE; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; PRURITUS; STATISTICAL SIGNIFICANCE; XEROSTOMIA;

ADULT; ANTIFUNGAL AGENTS; FEMALE; FLUCONAZOLE; HUMANS; INJECTIONS, INTRAVENOUS; LIVER DISEASES; MALE; MIDDLE AGED; PHOSPHORIC ACID ESTERS; PRODRUGS;

EID: 13444266126     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.02234.x     Document Type: Article

References (12)

1. Rex JH, Walsh TJ, Sobel JD et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 662-78.
2. Goa KL, Barradell LB, Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 1995; 50: 658-90.
3. Troke PF. Large-scale multicentre study of fluconazole in the treatment of hospitalised patients with fungal infections. Multicentre European Study Group. Eur J Clin Microbiol Infect Dis 1997; 16: 287-95.
4. Brammer KW, Farrow PR, Faulkner JK. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 1990; 12 (Suppl. 3): S318-S326.
5. Bentley A, Butters M, Green SP et al. The discovery and process development of a commercial route to the water soluble prodrug, fosfluconazole. Org Process Res Dev 2002; 6: 109-12.
6. Kawakami Y, Nagino K, Shinkai K, Sobue S, Abe M, Ishiko J. Nonclinical studies and clinical studies in fosfluconazole, A triazole antifungal agent (Prodif®). Folia Pharmacol Jpn 2004; 124: 41-51.
7. Sobue S, Sekiguchi K, Shimatani K, Tan K. Pharmacokinetics and safety of fosfluconazole after single intravenous bolus injection in healthy male Japanese volunteers. J Clin Pharmacol 2004; 44: 284-92.
8. Sobue S, Tan K, Layton G, Eve M, Sanderson JB. Pharmacokinetics of fosfluconazole and fluconazole following multiple intravenous administration of fosfluconazole in healthy male volunteers. Br J Clin Pharmacol 2004; 58: 20-5.
9. Sobue S, Tan K, Shaw L, Layton G, Hust R. Comparison of the pharmacokinetics of fosfluconazole and fluconazole after single intravenous administration of fosfluconazole in healthy Japanese and Caucasian volunteers. Eur J Clin Pharmacol 2004; 60: 247-53.
10. Sobue S, Tan K, Layton G, Leclerc V, Weil A. The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole. Br J Clin Pharmacol 2004; 57: 773-84.
11. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
12. Aweeka FT, Gottwald MD, Gambertoglio JG et al. Pharmacokinetics of fosphenytoin in patients with hepatic or renal disease. Epilepsia 1999; 40: 777-82.